急性肝衰竭（acute liver failure, ALF）发病急骤、预后差、死亡率高。本课题的立足点即在于从细胞和分子水平解析ALF的发生和进展机制并进行相关治疗策略的研究，以期促进全新且有效的ALF内科治疗方法的产生。Necroptosis是近年被阐明的一种细胞程序性死亡方式，其在肝脏疾病中的发生开始受到关注。本课题组拟在前期进行的国内多中心ALF临床资料调查和标本收集的基础上，结合动物预实验结果，采用病理学和分子生物学技术，分析阐述necroptosis在ALF中的发生机制以及程序性坏死特异性抑制剂-1对改善ALF预后的作用，为缓解ALF病情进展和降低死亡率提供重要支持。目前ALF领域的同类研究十分少见，而结合了临床标本的研究更是罕见。

Acute liver failure (ALF) is a complex condition characterized by rapid deterioration of liver function, poor prognosis and high mortality. Necroptosis is a recently recognized and accepted type of programmed cell death. As of now, the relationship between liver diseases and necroptosis has been given increasing attention to. In this study, we aim to clarify the pathogenesis of ALF from the view of necroptosis and explore new therapeutic strategies which can greatly improve the outcome of ALF..As the basis of this study, we performed a multi-center investigation of ALF and collected the corresponding clinical data and specimens. We also carried out preliminary animal experiments. In the current study, we will adopt pathological and biological techniques to analyze the mechanism of necroptosis and determine the impact of necrostatin-1 in the prognosis of ALF, which will contribute to alleviating ALF and decreasing the relative mortality. The similar studies in the research field of ALF are few, especially which is based on the human specimens.